s6y Neumora Therapeutics, Inc. POSASR

Neumora Therapeutics, Inc. POSASR, filed Mar 3, 2025: Consent of experts

Exhibit 23.2

Consent of Independent Registered Public Accounting Firm

We consent to the reference to our firm under the caption “Experts” and to the use of our report dated March 7, 2024, in Amendment No. 1 to the Registration Statement (Form S-3 No. 333-282460) and related Prospectus of Neumora Therapeutics, Inc. for the registration of common stock, preferred stock, debt securities, warrants and/or units.

 

/s/ Ernst & Young LLP
San Jose, California
March 3, 2025